The legacy context of general health and science information has long provided a foundation for understanding broad population-level risks and biological mechanisms. Within that framework, discussions of pharmaceutical safety and environmental exposures have typically been framed in terms of public health guidelines and clinical outcomes. As the focus narrows to occupational settings, however, the emphasis shifts from general awareness to specific exposure scenarios faced by workers in manufacturing, healthcare, and research environments. In mass production contexts, employees may encounter chemical agents, biologics, or pharmaceutical compounds as part of routine operations, raising questions about potential long-term health effects. One area of emerging interest involves the relationship between exposure to certain therapeutic agents and subsequent disease risk. For instance, the monoclonal antibody Avelumab, used in oncology, has been studied for possible associations with Merkel cell carcinoma development. While the general public may encounter such information through health science channels, occupational health professionals must consider whether workplace exposure to Avelumab or related compounds could elevate risk for this rare skin cancer. This transition from broad health literacy to targeted occupational concern requires careful examination of exposure pathways, dose-response relationships, and surveillance data specific to industrial settings.
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/; https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit in advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% do not respond or develop immune-related adverse events due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/).
The mechanistic pathway linking avelumab to Merkel cell carcinoma is not one of causation but of treatment. Avelumab is used to treat MCC, not to cause it. The evidence indicates that avelumab is a therapeutic agent for metastatic MCC, and its use is associated with clinical responses in a subset of patients. For patients who are refractory to avelumab, treatment options are limited. Studies have investigated the activity of ipilimumab plus nivolumab in avelumab-refractory MCC. In a retrospective study at three German sites, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab and nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC, noting that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC confirmed that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Regarding risk anchors, the adequacy of warnings about avelumab and MCC must be considered in the context of its approved use. Avelumab is indicated for the treatment of metastatic MCC, and its prescribing information includes warnings about immune-related adverse events, which are common with immune checkpoint inhibitors. The evidence does not suggest that avelumab causes MCC; rather, it is a treatment for the disease. Causation-related considerations for affected patients should focus on the natural history of MCC and the role of avelumab as a therapeutic agent. The timeline between exposure to avelumab and documented harm relates to the development of immune-related adverse events, which can occur during treatment, rather than the development of MCC itself. The evidence does not support a causal link between avelumab exposure and the initiation of MCC. In summary, avelumab is an established treatment for metastatic Merkel cell carcinoma, with evidence of efficacy in a subset of patients. The risk narrative should emphasize that avelumab is not a cause of MCC but a therapy for it. The evidence reviewed does not indicate that avelumab increases the risk of developing MCC; instead, it is used to manage the disease. For patients who do not respond to avelumab, alternative immune checkpoint inhibitor combinations may offer benefit.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor approved for metastatic MCC. Studies show it does not increase the risk of developing MCC; rather, it is used to manage the disease.
The JAVELIN Merkel 200 trial showed objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Response rates to PD-1/PD-L1 inhibition can reach up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/).
Common risks include immune-related adverse events, which can occur during treatment. About 50% of patients may not respond or may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.